Lead Product(s): Remimazolam
Therapeutic Area: Neurology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Cosmo Pharmaceuticals N.V.
Deal Size: $143.2 million Upfront Cash: $11.1 million
Deal Type: Licensing Agreement January 09, 2020
Acacia Pharma will be responsible for the marketing and distribution of ByFavo in the US in the context of its equity-for-product strategy.